ASXL1-mutant clonal hematopoiesis

Disease

1 paper2 findings

  • Humans1

Associations

2

Coronary artery disease incidence

upin humans1

1 study
  1. ASXL1-mutant clonal hematopoiesis is associated with coronary artery disease incidence in humans (18.7 vs 2.0 events/1,000 person-years).

    “Participants with ASXL1 CH subtype and low LE8 scores experienced the highest absolute CAD risk (18.7 vs 2.0 events/1,000 person-years in noncarriers with high LE8).”

    HumansLow Life's Essential 8 scores; compared with noncarriers with high scoresMedian 13.6-year follow-up

    Heart health linked to lower coronary risk in mutation carriers

    JACC. CardioOncology15 Oct 2026

Life's Essential 8 score

downin humans1OR 0.79

1 study
  1. Life's Essential 8 score is associated with ASXL1-mutant clonal hematopoiesis in humans (OR 0.79, 95% CI 0.75–0.83).

    “strongest for ASXL1 (OR: 0.79; 95% CI: 0.75-0.83; P < 0.001).”

    Humans

    Heart health linked to lower coronary risk in mutation carriers

    JACC. CardioOncology15 Oct 2026

More on Life's Essential 8 score

Latest

Nov 2025: 0Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 1Oct 2026: 12 in 12 months
JACC CardioOncology

Heart health linked to lower coronary risk in mutation carriers

A standard-deviation score increase was linked to coronary disease hazard ratios (relative event rates) of 0.74 in mutation carriers versus 0.68 in noncarriers.A standard-deviation score increase was linked to coronary disease hazard ratios (relative event rates) of 0.74 in mutation carriers versus 0.68 in noncarriers.

Cohort study of 427,295 UK Biobank participants, median 13.6-year follow-upPopulations

Limit: Coronary risk reduction from actively improving cardiovascular health scores was not measured

medRxiv

ASXL1-mutant clonal hematopoiesis links to aortic valve disease

In cohort data and cell models, ASXL1 mutations tracked with incident aortic stenosis and promoted valvular calcification that was reduced by IL-1 or IL-6 inhibition.In cohort data and cell models, ASXL1 mutations tracked with incident aortic stenosis and promoted valvular calcification that was reduced by IL-1 or IL-6 inhibition.

Preprint: cohort study of 449,109 peopleASXL1